-
Gamma-linolenic acid: Applied Research Workflows
2026-08-15
Build more reproducible inflammation, receptor-binding, and cell-death studies with Gamma-linolenic acid (GLA). This guide connects GLA’s established LTB4-related activity with practical assay design while clearly separating exploratory immune applications from findings reported for arachidonic acid.
-
Melittin for GPCR and GBM Signaling Research
2026-08-14
Melittin is a bioactive peptide for experimentally separating Gs- and Gi-linked signaling from downstream effects on viability, migration, and stress responses. This guide translates the miR-18a/ALOXE3 glioblastoma findings into practical assay designs, controls, and troubleshooting strategies without treating Melittin as a validated substitute for genetic pathway manipulation.
-
Metabolomics Reveals Carbapenemase-Linked Resistance
2026-08-14
A 2025 study used LC-MS/MS metabolomics and supervised machine learning to distinguish carbapenemase-producing Enterobacterales from non-CPE isolates in antibiotic-free cultures. The identified metabolite signatures provide mechanistic insight into resistance-associated metabolism and a possible route toward faster diagnostic testing.
-
AO/PI Staining Solution for Cell Viability
2026-08-13
AO/PI Staining Solution supports fluorescence-based cell counting when debris, red blood cells, or borderline membrane damage compromise dye-exclusion results. This workflow translates findings from a diabetic nephropathy study into practical live/dead assay choices for high-glucose podocyte experiments and other cell-injury models.
-
EV-Transferred ACLY Drives TAMs in HCC
2026-08-13
The reference study identifies extracellular vesicle-transferred ATP-citrate lyase as a metabolic signal that redirects monocytes toward immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its vesicle-engineering experiments further show that targeting this ACLY axis can weaken macrophage-mediated immune suppression and improve the rationale for combination treatment with PD-1 or PD-L1 blockade.
-
Indole-3-pyruvic Acid in Rheumatoid Arthritis
2026-08-12
The reference study identifies Indole-3-pyruvic acid (IPA) as a potentially protective tryptophan metabolite in rheumatoid arthritis and links its activity to AhR-dependent restoration of the Th17/Treg balance. By combining patient metabolomics, PBMC differentiation assays, and a collagen-induced arthritis model, the work provides a mechanistic basis for studying IPA in rheumatoid arthritis research while leaving clinical translation unresolved.
-
Talabostat mesylate: T-Cell Pyroptosis Workflows
2026-08-12
Talabostat mesylate, also called PT-100 or Val-boroPro, connects DPP biology with practical assays for FAP-positive tumor models and CARD8-dependent pyroptosis in resting human T cells. This guide separates target engagement from cell-death interpretation, with starting parameters and troubleshooting steps for reproducible cancer-immunology workflows.
-
Betaine hydrochloride in inflammation assay workflows
2026-08-11
Learn how to use Betaine hydrochloride as a controlled assay additive, matrix variable, and optional cell-culture supplement when studying inflammation-linked cancer biology. The workflow combines careful solution handling with orthogonal ELISA, qPCR, western blot, enzyme, and protease readouts inspired by recent esophageal cancer research.
-
Meropenem Trihydrate in Resistance Workflows
2026-08-11
Meropenem trihydrate provides a practical carbapenem antibiotic perturbation tool for susceptibility testing, resistance phenotyping, and infection-model development. Combined with LC-MS/MS metabolomics, it helps connect growth inhibition to the metabolic signatures associated with carbapenemase-producing Enterobacterales.
-
TAK-242 (Resatorvid) in TLR4 Assays
2026-08-10
This scenario-driven guide explains how TAK-242 (Resatorvid), a selective Toll-like receptor 4 (TLR4) inhibitor, can help researchers distinguish inflammatory signaling effects from genuine cytotoxicity in cell-based assays. It covers dose selection, DMSO handling, controls, interpretation, and vendor evaluation for SKU A3850.
-
LAG-3–TCR Proximity Controls T Cell Suppression
2026-08-09
A 2025 Cell study shows that LAG-3-mediated inhibition depends on spatial proximity to the T cell receptor, rather than MHC class II binding or CD4 association alone. The work identifies disruption of CD3ε–Lck signaling and develops an Fc-attenuated LAG-3/TCR bispecific antibody that suppresses pathogenic CD4+ and CD8+ T cells in autoimmune mouse models.
-
EV-Transferred ACLY Drives TAMs in HCC
2026-08-08
This study identifies extracellular vesicle-mediated transfer of ATP-citrate lyase (ACLY) as a metabolic mechanism that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its liposome-based validation strategy suggests that selectively disrupting ACLY activity in TAMs may improve anti-PD-1/PD-L1 responses while limiting broader systemic effects.
-
Fluorinated-Sorbitol Polyplexes for mRNA Vaccines
2026-08-07
The reference study develops fluorinated polyethyleneimine functionalized with sorbitol (PFS) as a polymeric mRNA carrier that addresses two major delivery barriers: cellular uptake and endosomal escape. In cell and mouse experiments, PFS supported luciferase expression and enabled a SARS-CoV-2 spike mRNA vaccine to generate neutralizing responses comparable to a Moderna LNP formulation.
-
MCC950 Sodium: Precision NLRP3 Inflammasome Inhibition in Di
2026-08-07
MCC950 sodium (CRID3 sodium salt) empowers researchers to dissect NLRP3-driven inflammation with nanomolar specificity, unlocking new dimensions in inflammatory and autoimmune disease research. This guide details experimental workflows, protocol upgrades, and troubleshooting insights, leveraging APExBIO’s high-purity MCC950 sodium to achieve reproducible, high-impact results.
-
EV-Transferred ACLY Reprograms Monocytes in Liver Cancer Imm
2026-08-06
This study uncovers how hepatocellular carcinoma (HCC) cells use extracellular vesicles to deliver ATP-citrate lyase (ACLY) to monocytes, driving their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The work reveals a novel mechanism of metabolic immune evasion in HCC and highlights ACLY as a potential target for improving immunotherapy.